Free Trial
NASDAQ:AVTE

Aerovate Therapeutics (AVTE) Stock Price, News & Analysis

$1.90
+0.02 (+1.06%)
(As of 09/13/2024 ET)
Today's Range
$1.89
$1.97
50-Day Range
$1.64
$2.01
52-Week Range
$1.25
$32.42
Volume
255,293 shs
Average Volume
517,229 shs
Market Capitalization
$54.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.25

Aerovate Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
18.4% Upside
$2.25 Price Target
Short Interest
Bearish
6.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.44mentions of Aerovate Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$375,450 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.74) to ($0.88) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.00 out of 5 stars

Medical Sector

592nd out of 922 stocks

Pharmaceutical Preparations Industry

280th out of 429 stocks

AVTE stock logo

About Aerovate Therapeutics Stock (NASDAQ:AVTE)

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

AVTE Stock Price History

AVTE Stock News Headlines

Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”
Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.
See More Headlines
Receive AVTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/12/2024
Today
9/14/2024
Next Earnings (Estimated)
11/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVTE
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.25
High Stock Price Target
$3.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+18.4%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-75,520,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.96 per share

Miscellaneous

Free Float
21,645,000
Market Cap
$54.85 million
Optionable
Optionable
Beta
1.03
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Timothy P. Noyes M.B.A. (Age 62)
    CEO & Director
    Comp: $936.9k
  • Mr. George A. Eldridge (Age 61)
    CFO & Treasurer
    Comp: $658.6k
  • Mr. Timothy J. Pigot (Age 53)
    Chief Commercial Officer
    Comp: $584.6k
  • Dr. Benjamin T. Dake Ph.D. (Age 48)
    Founder, President, COO & Secretary
    Comp: $435.5k
  • Dr. Marinus Verwijs Ph.D. (Age 48)
    Chief Technical Officer
    Comp: $439.88k
  • Dr. Ralph W. Niven M.B.A. (Age 64)
    M.R, Ph.D., Pharm.S, Chief Scientific Officer
    Comp: $372.33k
  • Mr. Hunter Gillies M.D. (Age 58)
    Chief Medical Officer
    Comp: $512.74k
  • Ms. Donna Dea
    Head of Regulatory Affairs
  • Ms. Susan Fischer
    Executive Vice President of Development Operations
  • Mr. Stephen K. Yu
    Senior Vice President of Quality

AVTE Stock Analysis - Frequently Asked Questions

How have AVTE shares performed this year?

Aerovate Therapeutics' stock was trading at $22.63 at the start of the year. Since then, AVTE stock has decreased by 91.6% and is now trading at $1.90.
View the best growth stocks for 2024 here
.

How were Aerovate Therapeutics' earnings last quarter?

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) announced its quarterly earnings data on Monday, August, 12th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.10.

When did Aerovate Therapeutics IPO?

Aerovate Therapeutics (AVTE) raised $100 million in an IPO on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share.

Who are Aerovate Therapeutics' major shareholders?

Top institutional shareholders of Aerovate Therapeutics include Atlas Venture Life Science Advisors LLC (6.24%), Deerfield Management Company L.P. Series C (4.90%), Affinity Asset Advisors LLC (0.69%) and SG Americas Securities LLC (0.62%). Insiders that own company stock include David S Grayzel, Hunter Gillies, George A Eldridge, Ralph Niven, Benjamin T Dake, Marinus Verwijs and Timothy P Noyes.
View institutional ownership trends
.

How do I buy shares of Aerovate Therapeutics?

Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AVTE) was last updated on 9/14/2024 by MarketBeat.com Staff

From Our Partners